PharmTech Drug Digest 11.20
News|Articles|July 29, 2013

Kemwell Biopharma Acquires Cirrus Pharmaceuticals Inc.

Author(s)Melanie Sena

Kemwell Biopharma announced that it has acquired Cirrus Pharmaceuticals Inc., a contract development services company based in Research Triangle Park, N.C.

Kemwell Biopharma, a global bio/pharmaceutical contract services company headquartered in Bangalore, India, announced that it has acquired Cirrus Pharmaceuticals Inc., a contract development services company based in Research Triangle Park, N.C., USA.

Since its inception in 1997, Cirrus has developed expertise in inhalation, parenteral, transdermal, topical and liquid dosage forms. It also offers stand-alone analytical services including stability studies.

Kemwell’s corporate objective is to build a leading global bio/pharmaceutical contract services company, said Anurag Bagaria, chairman and MD of Kemwell in a press statement. Cirrus will complement the existing contract services offered by Kemwell with early stage innovative product development. Kemwell will now provide customers with a complete solution from early development in the US to commercial manufacturing in Kemwell’s EMA, FDA, and PMDA approved facilities in India and Sweden.”

Source: Kemwell Biopharma


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.